Abstract:Transl Lung Cancer Res 2021;10(9):3858-3860 | https://dx.doi.org/10.21037/tlcr-21-650 We read with interest the KEYNOTE-598 trial (1), which did not meet its primary endpoints and was terminated early. Additional ipilimumab failed to amplify the efficacy of pembrolizumab in the ‘tumor proportion score (TPS) high’ population which could be attributed to several reasons. First, the clinical role of ipilimumab in addition to PD-1 antibody in the first line treatment for non-small cell lung cancer (NSCLC) is marginal, as previously demonstrated by CheckMate 227 part 1 (2). However, discernment of whether combining an immune checkpoint inhibitor (ICI) with chemotherapy is more efficient than ICI monotherapy in a PD-L1 high population is of great importance. Evidence from a meta-analysis showed that although objective response rate (ORR) as well as progression-free survival (PFS) were improved in the combination group, the overall survival (OS) benefit presented was identical (3). While an anti-PD-1 antibody plus chemotherapy performs better than an anti-PD-L1 antibody plus chemotherapy for first line NSCLC regardless of PD-L1 expression (4), the difference of anti-PD-1 versus anti-PD-L1 monotherapy in a PD-L1 high expression population is not significant, with results from TC3/IC3 of IMpower-110 for OS hazard ratio (HR) 0.59 [95% confidence interval (CI): 0.40 to 0.89] (5) and EMPOWER-Lung 1 showing an OS HR of 0.57 (95% CI: 0.42 to 0.77) (6). Although cross-trial comparisons are fraught with difficulties, we do have similar numerical median survival data of ICI monotherapy for this population. Hence, with similar PFS and OS results of the KEYNOTE-024 and KEYNOTE-598 trials, pembrolizumab monotherapy would remain the standard of care for the first line setting of PD-L1 high expressors at the current stage. Second, the toxicity profile of ipilimumab impacts the adverse event profile of dual ICI blockade. Adding ipilimumab was associated with a higher rate of grade 3–5 adverse events for NSCLC patients in KEYNOTE-598. With prior experience using ipilimumab in NSCLC, KEYNOTE-598 contributed evidence to the role of antiCTLA-4 into the first line treatment of NSCLC. According to data from the use of durvalumab plus tremelimumab in the MYSTIC trial (7), the toxicity of CTLA-4 inhibitors is not restricted to ipilimumab. In balancing the survival benefit and toxicity risk of PD-L1 high expressors, dual ICI blockade of PD-L1/CTLA-4 might not be an optimal choice. Toxicity profile of ipilimumab could be reduced with lower dose or longer interval of treatment, indicating the dedicate balance of efficacy versus toxicity of anti-CTLA-4 antibody. Third, the underlying biologic mechanisms might explain the failure of KEYNOTE-598. The PD-1/PDL1 pathway is a major immune-related mechanism in these cancers, but the tumor immune microenvironment Letter to the Editor

Dual Immune Checkpoint Blockade for Non-Small Cell Lung Cancer Patients with PD-L1 High Expression: Calling an End?